We report the successful use of daptomycin in a child with methicillin-resistant Staphylococcus aureus endocarditis with persistent bacteremia and clinical deterioration, despite treatment with vancomycin and rifampicin. She had acute kidney injury, requiring daptomycin dosage adjustment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/INF.0000000000000958 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetic/pharmacodynamic analysis of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults by Monte Carlo simulation.
J Glob Antimicrob Resist
November 2024
Department of Hematology, Tianjin First Central Hospital, Tianjin, PR China.
Objective: The objective of this study was to investigate the cumulative fraction of response of various dosage regimens of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults.
Methods: Monte Carlo simulations were performed using previously published pharmacokinetic parameters and pharmacodynamic data to evaluate the efficacy of the simulated dosage strategies in terms of area under the concentration-time curve/minimum inhibitory concentration targets of tedizolid.
Results: According to the results of the Monte Carlo simulations, currently approved dosage regimens of tedizolid phosphate were effective in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by methicillin-susceptible S.
Retrospective analysis of antimicrobial susceptibility profiles of non- species from a tertiary hospital and reference laboratory, 2012-2023.
J Clin Microbiol
December 2024
Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
A total of 1,925 isolates were tested for antimicrobial susceptibility at the Mayo Clinic Microbiology laboratory (Rochester, Minnesota) from January 2012 to March 2023, with (35.6%) and (24.4%) identified as the predominant species.
View Article and Find Full Text PDFReal-World Clinical Characteristics and Outcomes with Daptomycin Use in Pediatric Patients: A Retrospective Case Series.
Antibiotics (Basel)
September 2024
Department of Pharmacy Services, Medical University of South Carolina Shawn Jenkins Children's Hospital, Charleston, SC 29425, USA.
Introduction: Daptomycin (DAP) is a cyclic lipopeptide that exhibits potent in vitro activity against many drug-resistant gram-positive organisms, including methicillin-resistant (MRSA) and vancomycin-resistant enterococci (VRE). Despite substantial reports evaluating the clinical outcomes of DAP within the adult population, real-world data are lacking in children. The primary goal of this evaluation was to describe the clinical characteristics and outcomes of DAP use in pediatric patients across a wide range of infections.
View Article and Find Full Text PDFTicagrelor alters the membrane of and enhances the activity of vancomycin and daptomycin without eliciting cross-resistance.
mBio
October 2024
Laboratory of Cardiology, GIGA Research Institute, University of Liège, Liège, Belgium.
Infections with multidrug-resistant bacteria pose a major healthcare problem which urges the need for novel treatment options. Besides its potent antiplatelet properties, ticagrelor has antibacterial activity against Gram-positive bacteria, including methicillin- and vancomycin-resistant (MRSA and VRSA). Several retrospective studies in cardiovascular patients support an antibacterial effect of this drug which is not related to its antiplatelet activity.
View Article and Find Full Text PDFDaptomycin treatment for persistent bacteremia in a pediatric solid organ transplant recipient: Case report and literature review.
J Infect Chemother
August 2024
Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan; Department of Pediatrics, Hamamatsu University School of Medicine, Shizuoka, Japan. Electronic address:
Article Synopsis
- The text discusses the limited information on the use of daptomycin for treating persistent bacteremia in pediatric patients, especially those who have undergone solid organ transplantation.
- It presents a case study of an eight-year-old girl whose persistent bacteremia, caused by Staphylococcus epidermidis, was successfully treated with daptomycin after adjusting the dosage due to her renal dysfunction.
- A literature review revealed very few cases of daptomycin use in children with persistent bacteremia, emphasizing the need for more research on its clinical efficacy and pharmacokinetics in this special patient group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!